Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) EPS (Basic) (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed EPS (Basic) for 2 consecutive years, with -$3.76 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 73.76% to -$3.76 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.21 through Dec 2025, up 72.68% year-over-year, with the annual reading at -$4.19 for FY2025, 72.51% up from the prior year.
  • EPS (Basic) hit -$3.76 in Q4 2025 for Xilio Therapeutics, down from -$0.11 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.11 in Q3 2025 to a low of -$14.33 in Q4 2024.